Long-acting HIV injections show success in patients with struggles to take daily pills

Antibody prophylaxis may mask subclinical SIV infections in macaques

Broadly neutralizing antibodies (bNAbs) show potential to prevent human immunodeficiency virus (HIV-1) infection in humans1. However, there are limited data on the antibody concentrations required to prevent infection. Clinical trials of bNAb prophylaxis have demonstrated partial efficacy2, but the sampling frequency typically does not allow precise timing of infection events and concurrent antibody levels. Here, using simian immunodeficiency vi…

Long-acting HIV injections show success in patients with struggles to take daily pills

UCSF researchers are the first to demonstrate that the approach works for the patients who need it the most.

Long-acting injectable HIV therapy offers hope for those unable to take pills

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found.

Situational Assessment and Epidemiology of HIV, HBV and HCV Among People Who Use and Inject Drugs in Ghana – hepCoalition

Rapid assessment study findings reveal challenging conditions for people who use and inject drugs in Ghana coupled with a relatively high prevalence of HIV and hepatitis C compared to the general population. Prevention / People who inject drugs